Ensysce Biosciences (ENSC) Projected to Post Quarterly Earnings on Friday

Ensysce Biosciences (NASDAQ:ENSC) will likely be announcing its earnings results before the market opens on Friday, March 21st. Analysts expect the company to announce earnings of ($2.74) per share and revenue of $0.25 million for the quarter.

Ensysce Biosciences (NASDAQ:ENSC) last posted its quarterly earnings data on Monday, March 10th. The company reported ($2.90) EPS for the quarter, missing the consensus estimate of ($2.74) by ($0.16). Ensysce Biosciences had a negative return on equity of 292.81% and a negative net margin of 179.26%. The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $0.25 million. On average, analysts expect Ensysce Biosciences to post $-8 EPS for the current fiscal year and $-13 EPS for the next fiscal year.

Ensysce Biosciences Price Performance

NASDAQ:ENSC opened at $3.88 on Wednesday. Ensysce Biosciences has a one year low of $2.12 and a one year high of $14.67. The company’s 50-day simple moving average is $6.09 and its 200 day simple moving average is $6.40. The firm has a market capitalization of $5.45 million, a P/E ratio of -0.14 and a beta of 0.64.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc, a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.